Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes

Journal of Neuroimmunology

Volumn 176, Issue 1-2, 2006, Pages 95-105

  Xu, Jihong ^a   Chavis, Janet A ^a   Racke, Michael K ^b   Drew, Paul D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Astrocyte; Chemokine; Cytokine; PPAR

Indexed keywords

ALITRETINOIN; ANTIINFLAMMATORY AGENT; CIPROFIBRATE; CYTOKINE; FENOFIBRATE; GEMFIBROZIL; HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUCINE METHYL ESTER; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL TYPE; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; GENE EXPRESSION; INFLAMMATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANIMALS; ASTROCYTES; CHEMOKINES; CYTOKINES; DNA; INFLAMMATION; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PPAR ALPHA; RETINOID X RECEPTORS;

EID: 33746079214     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.04.019     Document Type: Article

References (54)

1. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., and Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4 (2001) 1116-1122
2. Benveniste E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 75 (1997) 165-173
3. Bernardo A., Levi G., and Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12 (2000) 2215-2223
4. Castrillo A., Diaz-Guerra M.J., Hortelano S., Martin-Sanz P., and Bosca L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20 (2000) 1692-1698
5. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 164 (2000) 1364-1371
6. Coyle P.K. The neuroimmunology of multiple sclerosis. Adv. Neuroimmunol. 6 (1996) 143-154
7. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14, 643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 169 (2002) 6806-6812
8. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., and Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 168 (2002) 2795-2802
9. De Keyser J., Zeinstra E., and Frohman E. Are astrocytes central players in the pathophysiology of multiple sclerosis?. Arch. Neurol. 60 (2003) 132-136
10. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
11. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
12. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508-2515
13. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., and Racke M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148 (2004) 116-126
14. Drew P.D., and Chavis J.A. The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells. J. Neuroimmunol. 115 (2001) 28-35
15. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., and Heneka M.T. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
16. Fenyk-Melody J.E., Garrison A.E., Brunnert S.R., Weidner J.R., Shen F., Shelton B.A., and Mudgett J.S. Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. J. Immunol. 160 (1998) 2940-2946
17. Holley J.E., Gveric D., Newcombe J., Cuzner M.L., and Gutowski N.J. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol. Appl. Neurobiol. 29 (2003) 434-444
18. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
19. Kahl K.G., Schmidt H.H., Jung S., Sherman P., Toyka K.V., and Zielasek J. Experimental autoimmune encephalomyelitis in mice with a targeted deletion of the inducible nitric oxide synthase gene: increased T-helper 1 response. Neurosci. Lett. 358 (2004) 58-62
20. Kassiotis G., Pasparakis M., Kollias G., and Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 29 (1999) 774-780
21. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., Kohno M., Yamada R., Hla T., and Sano H. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106 (2000) 189-197
22. Kennedy K.J., and Karpus W.J. Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis. J. Clin. Immunol. 19 (1999) 273-279
23. Kennedy K.J., Strieter R.M., Kunkel S.L., Lukacs N.W., and Karpus W.J. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J. Neuroimmunol. 92 (1998) 98-108
24. Kielian T., and Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 71 (2003) 315-325
25. Lee C.H., Olson P., and Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
26. Li W.D., Lee J.H., and Price R.A. The peroxisome proliferator-activated receptor gamma 2 Pro12Ala mutation is associated with early onset extreme obesity and reduced fasting glucose. Molec. Genet. Metab. 70 (2000) 159-161
27. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172 (2004) 5790-5798
28. Mahad D.J., and Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol. 15 (2003) 23-32
29. Martin R., and McFarland H.F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32 (1995) 121-182
30. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P., and Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90 (2002) 703-710
31. Mason J.L., Suzuki K., Chaplin D.D., and Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 21 (2001) 7046-7052
32. McCarthy K.D., and de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85 (1980) 890-902
33. Natarajan C., and Bright J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 3 (2002) 59-70
34. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
35. Raine C.S. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J. Neuroimmunol. 77 (1997) 135-152
36. Ricote M., Huang J.T., Welch J.S., and Glass C.K. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J. Leukoc. Biol. 66 (1999) 733-739
37. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
38. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103-108
39. Sahrbacher U.C., Lechner F., Eugster H.P., Frei K., Lassmann H., and Fontana A. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur. J. Immunol. 28 (1998) 1332-1338
40. Sean Riminton D., Korner H., Strickland D.H., Lemckert F.A., Pollard J.D., and Sedgwick J.D. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J. Exp. Med. 187 (1998) 1517-1528
41. Simpson J.E., Newcombe J., Cuzner M.L., and Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84 (1998) 238-249
42. Smith M.E. Phagocytic properties of microglia in vitro: implications for a role in multiple sclerosis and EAE. Microsc. Res. Tech. 54 (2001) 81-94
43. Sobel R.A. The pathology of multiple sclerosis. Neurol. Clin. 13 (1995) 1-21
44. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., and Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103 (1999) 807-815
45. Sriram S., and Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurol. 48 (1997) 464-470
46. Stinissen P., Medaer R., and Raus J. Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis. Mult. Scler. 4 (1998) 203-211
47. Storer P.D., Xu J., Chavis J., and Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161 (2005) 113-122
48. Storer P.D., Xu J., Chavis J.A., and Drew P.D. Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. J. Neurosci. Res. 80 (2005) 66-74
49. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., and Wu G.D. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104 (1999) 383-389
50. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. [see comment]. N. Engl. J. Med. 338 (1998) 278-285
51. van der Veen R.C., Dietlin T.A., and Hofman F.M. Tissue expression of inducible nitric oxide synthase requires IFN-gamma production by infiltrating splenic T cells: more evidence for immunosuppression by nitric oxide. J. Neuroimmunol. 145 (2003) 86-90
52. Xiao B.G., and Link H. Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis. Cell. Mol. Life Sci. 56 (1999) 5-21
53. Xu J., Storer P.D., Chavis J.A., Racke M.K., and Drew P.D. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 81 (2005) 403-411
54. Zeinstra E., Wilczak N., and De Keyser J. Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. J. Neuroimmunol. 135 (2003) 166-171